Why the study?
Vaccine shortages and hesitancy hinder herd immunity, and the reactogenicity and immunogenicity of heterologous ChAdOx1-S and mRNA vaccination regimens remained unclear.
Does heterologous COVID-19 vaccination with ChAdOx1-S and mRNA vaccines improve immunogenicity and safety compared to homologous vaccination?
Population
Participants receiving COVID-19 vaccination across included studies
Comparison
Heterologous vaccination (ChAdOx1-S and mRNA vaccines) vs homologous vaccination
Design
Systematic review following PRISMA guidelines
Authors
Loading...
Supports heterologous regimens to enhance responses amid shortages; extends RCT data via systematic synthesis.
Does heterologous COVID-19 vaccination with ChAdOx1-S and mRNA vaccines improve immunogenicity and safety compared to homologous vaccination?
Heterologous prime-boost COVID-19 vaccination with ChAdOx1-S and mRNA vaccines yields robust immunogenicity and appears safe, offering a strategy to mitigate vaccine shortages.
Ho et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: